Strategic Overview: As of April 14, 2026, we are in the critical pre-implementation window for the most significant global pediatric regulatory shifts in a decade. With only weeks remaining until the May 2026 implementation of new incentives in Japan and China, sponsors must reconcile the 24-month “Timing Gap” between EMA and FDA milestones. This analysis […]
Executive Summary: As of March 2026, pediatric drug development has moved beyond simple “trial size reduction” to a strategy of Mechanistic Justification. While the finalized ICH E11A (2025) guideline provides the high-level extrapolation tree, the February/March 2026 FDA Modernization Pack—specifically the Plausible Mechanism Framework and the new Bayesian Methodology Standards—has redefined the “totality of evidence.”
Executive Summary On March 18, 2026, the FDA issued a landmark draft guidance on New Approach Methodologies (NAMs), signaling a transformative shift in the preclinical landscape. For small biotechs, the guidance provides a formal pathway to use in silico models, organ-on-a-chip technology, and other non-animal methods to support regulatory decision-making. This is no longer just
Executive Summary For a long time, the pharmaceutical industry viewed Clinical Pharmacology models as helpful supporting characters. They were tools used to guide a trial design or help justify a specific dose. As we move through 2026, a fundamental shift has taken place. The FDA and EMA have moved from Model Informed to Model Integrated
The MIE Shift: When the Model Becomes the Primary Evidence for FDA Approval Read More »
Beyond Biosimilarity: The 2026 Strategic Blueprint for Day 1 Interchangeability Executive Summary For over a decade, the Interchangeable designation was the most expensive badge of honor in the biosimilar industry, typically requiring a multi-million dollar clinical switching trial. As of early 2026, the regulatory wall has collapsed. Following the FDA’s pivotal June 2024 guidance and
Beyond Biosimilarity: The 2026 Strategic Blueprint for Day 1 Interchangeability Read More »
Many 2026 INDs are already being scoped. Budgets are being finalized, CROs are being shortlisted, and timelines are being compressed. In that environment, clinical pharmacology often becomes something to be delivered rather than something to be designed. Analyses are commissioned because the IND needs them, not because a decision requires them. The risk here is
Introduction: The High Cost of “Checking the Box” For emerging biotech companies, cash runway is oxygen. The cost of developing a new drug has skyrocketed to over $2 billion, with the clinical phase consuming the vast majority of that budget. Every month spent in clinical development burns capital, shortens patent life, and delays the path
When to Use PopPK/PD, Exposure Response, PBPK, and QSP, and When Not To 1. Introduction: Why Quantitative Pharmacology Matters Model informed development has shifted from optional exploratory analysis to a central part of decision making. Most high value decisions such as target viability, mechanism plausibility, first in human (FIH) dose selection, Phase 2 dose justification,
A Practical Guide to Quantitative Pharmacology in Drug Development Read More »
Model-informed analyses are increasingly recognized by regulators and sponsors as credible evidence—especially when the question is clear, the model is verified for purpose, and uncertainties are transparent. This article reviews real submissions where M&S supported dose selection, regimen bridging, DDI labeling, pediatric dosing, and systems-level benefit–risk insight. Contents Introduction Case 1 — Exposure Bridging (Pembrolizumab
A joint evolution in FDA and EMA guidance signals a paradigm shift toward efficiency, science, and patient access. 1. The Changing Landscape For nearly two decades, biosimilar development followed a familiar path: prove similarity through large, comparative efficacy studies against the reference product. These studies—costly, time-consuming, and often redundant—became the accepted norm. In 2025, both
Biosimilar Development in 2025: From Comparative Trials to Analytical Confidence Read More »
